Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Filings indexed 2,288 across all filing types
Latest filing 2021-12-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
第十届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution, specifically the election of the chairman of the supervisory board. It includes details about the meeting date, participants, voting results, and compliance with legal and regulatory requirements. There is no financial data, no discussion of financial results, no mention of annual or interim reports, nor any indication of a shareholder vote result on dividends or other matters. The document is a corporate governance announcement related to board management changes, specifically the election of a supervisory board chairman. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification letter, so it is not RPA or RNS. Confidence is high due to clear content and context.
2021-12-09 Chinese
关于首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the company's first share repurchase (buyback) activity. It details the board meeting approval, the repurchase plan, the number of shares repurchased, prices, and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data but focuses on the share repurchase event itself. The length is short (1426 characters) and it is a formal announcement of a share buyback, fitting the category of Transaction in Own Shares (POS).
2021-12-03 Chinese
关于公司办公地址及联系电话变更的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement (709 characters) about the change of the company's office address and contact phone number. It does not contain financial data, regulatory certifications, or detailed report content. It is not an annual report, earnings release, or any financial filing. It is a general regulatory announcement informing investors about contact information changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-02 Chinese
回购报告书
Transaction in Own Shares Classification · 95% confidence The document is titled as a "回购报告书" which translates to "Share Repurchase Report" or "Buyback Report." It details the company's plan to repurchase its own shares, including the purpose, amount, price limits, funding source, implementation period, and risk factors. It also includes information about board approvals, independent director opinions, and disclosures related to insider trading and shareholding changes. The document is comprehensive and contains substantive details about the share repurchase program, not just an announcement or a brief notice. This matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares (share repurchase/issuance). The document length (8610 characters) and detailed content confirm it is the report itself, not merely an announcement or certification. Therefore, the correct classification is POS with high confidence.
2021-11-30 Chinese
关于控股子公司重组人生长激素注射液新适应症获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industry Group Co., Ltd. regarding the approval of an additional indication for a recombinant human growth hormone injection by the National Medical Products Administration. It is a regulatory announcement about product registration and approval, not a financial report, management change, or shareholder meeting material. The document is short (600 characters) and serves as an official notice of regulatory approval, fitting best under general regulatory announcements.
2021-11-30 Chinese
关于公司持股5%以上股东增持公司股票的自愿性公告
Major Shareholding Notification Classification · 100% confidence The document is a voluntary announcement by a shareholder holding more than 5% of the company's shares about increasing their shareholding. It details the shareholder's name, the number of shares before and after the increase, the method of purchase, and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion. This fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2021-11-26 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.